

# Phase I trial: MM-120-101

|                          |                             |   |
|--------------------------|-----------------------------|---|
| <b>Submission date</b>   | <b>Recruitment status</b>   | <input type="checkbox"/> Prospectively registered               |
| 14/05/2024               | No longer recruiting        | <input type="checkbox"/> Protocol                               |
| <b>Registration date</b> | <b>Overall study status</b> | <input type="checkbox"/> Statistical analysis plan              |
| 21/05/2024               | Deferred                    | <input type="checkbox"/> Results                                |
| <b>Last Edited</b>       | <b>Condition category</b>   | <input type="checkbox"/> Individual participant data            |
| 13/01/2026               | Other                       | <input checked="" type="checkbox"/> Record updated in last year |

## Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

## Contact information

### Type(s)

Public, Scientific, Principal investigator

### Contact name

Dr David Gregory

### Contact details

11 Tiger Court, Kings Drive Prescot  
Liverpool  
United Kingdom  
L34 1BH  
+44 (0)151 4824700  
davidgregory@macplc.com

### Type(s)

Scientific

### Contact name

None Jo Brady

### Contact details

Senior Consultant  
DLRC Regulatory Consultancy  
Suite 201, The Nexus Building, Broadway  
Letchworth Garden City  
United Kingdom  
Herts SG6 3TA

+44 01462 372472  
Jo.Brady@dlrcgroup.com

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### Integrated Research Application System (IRAS)

1007602

### ClinicalTrials.gov (NCT)

Nil known

### Protocol serial number

IRAS 1007602

## Study information

### Scientific Title

Phase I trial: MM-120-101

### Study objectives

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### Ethics approval required

Ethics approval required

### Ethics approval(s)

approved 18/09/2023, Wales Research Ethics Committee 1 Cardiff (Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road, East Cardiff, CF11 9AB, United Kingdom; 02922940912; wales.rec1@wales.nhs.uk), ref: 23/WA/0112

### Study design

Phase 1 study in 30 healthy volunteers

### Primary study design

Other

### Study type(s)

Other, Safety

### Health condition(s) or problem(s) studied

Healthy volunteers

### Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Intervention Type**

Drug

### **Phase**

Phase I

### **Drug/device/biological/vaccine name(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Primary outcome(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Key secondary outcome(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Completion date**

19/12/2023

## **Eligibility**

### **Key inclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Participant type(s)**

Healthy volunteer

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Sex**

All

### **Total final enrolment**

0

## **Key exclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

## **Date of first enrolment**

13/10/2023

## **Date of final enrolment**

04/12/2023

## **Locations**

### **Countries of recruitment**

United Kingdom

England

### **Study participating centre**

#### **MAC Clinical Research Liverpool**

11 Tiger Court

King's Business Park

Liverpool

England

L34 1BH

### **Study participating centre**

#### **MAC Clinical Research Manchester**

Citylabs 1.0

Nelson St

Manchester

England

M13 9NQ

## **Sponsor information**

### **Organisation**

Mind Medicine Inc

## **Funder(s)**

**Funder type**

Research organisation

**Funder Name**

Mind Medicine Inc

## Results and Publications

### Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Not expected to be made available

#### Study outputs

| Output type                                   | Details                       | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|-------------------------------|--------------|------------|----------------|-----------------|
| <a href="#">Participant information sheet</a> | Participant information sheet | 11/11/2025   | 11/11/2025 | No             | Yes             |